The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Results of the PROMISE study of ~30,000 individuals screened for monoclonal gammopathies
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the PROMISE study (NCT03689595), which screened approximately 30,000 high-risk individuals for monoclonal gammopathies. The study found a high prevalence of 14% in people of African descent, with age, sex, and family history of myeloma being strong predictive factors. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
